+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) - Drugs In Development, 2021

  • ID: 5359558
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 95 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AnaptysBio Inc
  • ConMed Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co Ltd
  • Novartis AG
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) - Drugs In Development, 2021, provides an overview of the Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline landscape.

Nasal polyps (Nasal polyposis) is an inflammatory condition develops in the nasal lining of nose. They are non-cancerous growths. Signs and symptoms include runny nose, postnasal drip, headache, snoring and loss of sense of taste. Risk factors include asthma, aspirin sensitivity, cystic fibrosis, Churg-strauss syndrome and allergic fungal sinusitis. Treatment includes steroid medications.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasal Polyps (Nasal Polyposis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3, 1 and 1 respectively.

Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AnaptysBio Inc
  • ConMed Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co Ltd
  • Novartis AG
Introduction
  • Report Coverage
Nasal Polyps (Nasal Polyposis) - Overview

Nasal Polyps (Nasal Polyposis) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Nasal Polyps (Nasal Polyposis) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Nasal Polyps (Nasal Polyposis) - Companies Involved in Therapeutics Development
  • AnaptysBio Inc
  • ConMed Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co Ltd
  • Novartis AG
  • OptiNose Inc
  • Pfizer Inc
  • Suzhou Connect Biopharmaceuticals Ltd
Nasal Polyps (Nasal Polyposis) - Drug Profiles

benralizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CBP-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CM-310 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
etokimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
fevipiprant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
fluticasone propionate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
mepolizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
omalizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
PF-06817024 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Nasal Polyps (Nasal Polyposis) - Dormant Projects

Nasal Polyps (Nasal Polyposis) - Discontinued Products

Nasal Polyps (Nasal Polyposis) - Product Development Milestones

Featured News & Press Releases
  • Apr 12, 2021: Novartis receives FDA approval of Xolair (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients
  • Dec 08, 2020: FDA accepts GSK’s filing of Nucala (mepolizumab) for use in chronic rhinosinusitis with nasal polyps
  • Dec 01, 2020: Genentech announces FDA approval of Xolair (omalizumab) for adults with nasal polyps
  • Oct 29, 2020: GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additional eosinophil-driven diseases
  • Sep 10, 2020: AstraZeneca reports positive results from OSTRO trial of Fasenra
  • Aug 10, 2020: AnaptysBio reports top-line data from interim analysis of ECLIPSE phase 2 clinical trial of Etokimab in chronic rhinosinusitis with nasal polyps
  • Aug 06, 2020: Novartis receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps
  • Jul 08, 2020: Optinose announces XHANCE co-promotion agreement with Kaléo
  • Jun 26, 2020: Novartis receives positive CHMP opinion for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps
  • Apr 03, 2020: Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps
  • Dec 17, 2019: Optinose announces peer-reviewed publication of the fourth major XHANCE registration trial
  • Dec 11, 2019: FDA agrees to review Novartis’ sBLA of Xolair to treat nasal polyps
  • Sep 12, 2019: Optinose announces $150 million debt financing from Pharmakon
  • Jun 03, 2019: Xolair (Omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
  • Feb 19, 2019: Optinose announces issuance of four additional U.S. patents covering XHANCE
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Nasal Polyps (Nasal Polyposis), 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Nasal Polyps (Nasal Polyposis) - Pipeline by AnaptysBio Inc, 2021
  • Nasal Polyps (Nasal Polyposis) - Pipeline by ConMed Biosciences Inc, 2021
  • Nasal Polyps (Nasal Polyposis) - Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Nasal Polyps (Nasal Polyposis) - Pipeline by GlaxoSmithKline Plc, 2021
  • Nasal Polyps (Nasal Polyposis) - Pipeline by Kyowa Kirin Co Ltd, 2021
  • Nasal Polyps (Nasal Polyposis) - Pipeline by Novartis AG, 2021
  • Nasal Polyps (Nasal Polyposis) - Pipeline by OptiNose Inc, 2021
  • Nasal Polyps (Nasal Polyposis) - Pipeline by Pfizer Inc, 2021
  • Nasal Polyps (Nasal Polyposis) - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2021
  • Nasal Polyps (Nasal Polyposis) - Dormant Projects, 2021
  • Nasal Polyps (Nasal Polyposis) - Discontinued Products, 2021
List of Figures
  • Number of Products under Development for Nasal Polyps (Nasal Polyposis), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • AnaptysBio Inc
  • ConMed Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co Ltd
  • Novartis AG
  • OptiNose Inc
  • Pfizer Inc
  • Suzhou Connect Biopharmaceuticals Ltd
Note: Product cover images may vary from those shown
Adroll
adroll